The discomfort of abdomen along with altered function of bowel is the general characteristic of Irritable Bowel Syndrome. Irritable Bowel Syndrome is not a threat to life type disorder but it affects the quality of living of the sufferer. Even though it is inexperienced, Irritable Bowel Syndrome market is large in provision of volume with very few facts of pharmacotherapies specify for the cure of disorder and is categorised also by important unmet requirements. LInzess is used for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation treatment in people above the age of 18 years. When the cause of the constipation is not known it is known as “idiopathic”. Weather Linzes is safe if administered to the children below the age of 18 years is not clear as of now. But one thing is very clear; it cannot be given to children below 6 years of age. It is harmful to them. Linzess should not be taken unless prescribed by the physician for the blockage of bowel. The doctor should be informed about the patients’ other medical conditions, being pregnant or want to plan for it because it is unknown if it proves harmful to the foetus. For the nursing mothers it can be harmful by passing through the milk to the baby which is yet to be discovered. Even all other medication should be declared to the doctor before taking this medicine, which should cover prescribed and non- prescribed medicine like herbal supplement and vitamins. Linzess has severe side effects which in most cases is diarrhea and can be really very sever at times. Mostly diarrhea starts within two weeks of starting this medicine. Hence if so, the patient should stop taking Linzess and consult the doctor immediately. It should be administered as per the doctor’s advice and should be kept at room temperature away from the reach of any child. Ironwood Pharmaceuticals has discovered this product originally. The commercialization and development of Linzess was carried out by a number of authorizing conformities with Forest in US, Astellas in Japan, and Almirall in EU. Linzess has been in phase III of expansion as prospective cure of IBS-C in Japan till the November 2014, and it is for that reason at present not accessible in the market.
Table of Contents Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 8 3 Disease Overview 10 3.1 Etiology and Pathophysiology 10 3.1.1 Etiology 10 3.1.2 Pathophysiology 11 3.2 Classification 11 3.3 Symptoms 12 3.4 Prognosis 13 3.5 Quality of Life 13 4 Disease Management 14 4.1 Diagnosis and Treatment Overview 14 4.1.1 Diagnosis 14 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 16 4.1.3 Clinical Practice 19 5 Competitive Assessment 21 5.1 Overview 21 6 Linzess (linaclotide) 23 6.1 Overview 23 6.2 Efficacy 24 6.3 Safety 28 6.4 SWOT Analysis 29 6.5 Forecast 29 7 Appendix 31 7.1 Bibliography 31 7.2 Abbreviations 34 7.3 Methodology 36 7.4 Forecasting Methodology 36 7.4.1 Diagnosed IBS Patients 36 7.4.2 General Pricing Assumptions 37 7.4.3 Individual Drug Assumptions 38 7.4.4 Generic Erosion 38 7.5 Primary Research - KOLs Interviewed for This Report 39 7.6 Primary Research - Prescriber Survey 41 7.7 About the Authors 42 7.7.1 Analyst 42 7.7.2 Therapy Area Director 42 7.7.3 Global Head of Healthcare 43 7.8 About GlobalData 44 7.9 Disclaimer 44
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...October 15, 2015
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...October 30, 2015
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...October 6, 2015
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...October 13, 2015
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...October 15, 2015
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-202-9519
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.